Gt biopharma reports first quarter 2023 financial results and provides corporate update

Brisbane, california, may 15, 2023 (globe newswire) -- gt biopharma, inc. (the “company”) (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced first quarter 2023 results for the period ended march 31, 2023.

GTBP Ratings Summary

GTBP Quant Ranking